F1 Pharma receives funding for the project in the Fast Track programme intended for Small, Middle Enterprises (SMEs), small projects
On 1 December 2017 the Management of F1 Pharma sp. z o.o. has signed a contract agreement with the National Centre for Research and Development (NCBiR) for the subsidization of the project entitled “The development of innovative forms of mucolytic drugs, suitable for application to children, elderly persons and persons suffering from esophageal dysphagia”
The project is co-funded by the European Union from the European Regional Development Fund, under the Intelligent Development Operational Programme, 2014-2020, Measure 1.1 - R&D Business Projects, Sub-Measure 3/1.1.1/2017 - Industrial research and development works carried out by companies, POIR in 2017 (Competition 3/1.1.1/2017).
The aim of this project it to carry out R&D works in order to develop two significantly improved medical products which contain a mucoactive substance used for the treatment of seasonal illnesses and a genetic illness – cystic fibrosis. The developed products will be characterized by modern form of drug application. F1 Pharma has already began working on this project. The project will run for 12 months, until the end of October 2018 and will end with pilot scale batches manufacturing according to GMP conditions.
Value of project: 1 470 445.00 PLN
EU Funding: 1 099 101.00 PLN